| Dr Katherine A Pollard, MD | |
|
1701 N Senate Blvd, Indianapolis, IN 46202 | |
| (317) 880-3881 | |
| Not Available |
| Full Name | Dr Katherine A Pollard |
|---|---|
| Gender | Female |
| Speciality | Pulmonary Disease |
| Experience | 11 Years |
| Location | 1701 N Senate Blvd, Indianapolis, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063857936 | NPI | - | NPPES |
| 201169600 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | 01074261A (Indiana) | Secondary |
| 207P00000X | Emergency Medicine | 01074261A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Indiana University Health | Indianapolis, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Indiana Clinic Critical Care Llc | 3678600988 | 206 |
| Indiana University Health Care Associates Inc | 5799755864 | 882 |
News Archive
Optimer Pharmaceuticals, Inc. has announced that the United States Patent and Trademark Office issued a production patent (U.S. Patent No. 7,507,564) covering steps used in the manufacture of fidaxomicin, which is currently in its second Phase 3 clinical trial for the treatment of Clostridium difficile infection, or CDI.
Joachim Scholz from Massachusetts General Hospital in Boston, USA and his colleagues studied the symptoms and signs of patients with peripheral neuropathic pain (nerve pain such as sciatica) and non-neuropathic (non-nerve) low back pain to identify the best clinical questions and physical tests for diagnosing pain types.
ValGenesis, Inc., a world-class provider of Validation Lifecycle Management Systems (VLMS), announced today that its innovative ValGenesis Suite 2.5 has achieved SAP certification as powered by the SAP NetWeaver technology platform. Attaining this certified integration status deepens ValGenesis' active and on-going commitment to SAP® solutions.
The U.S. Food and Drug Administration has awarded Rare Pediatric Disease Designation (RPDD) for diffuse intrinsic pontine glioma (DIPG) and Orphan Drug Designation for treatment of malignant glioma to OKN-007, an investigational drug discovered at the Oklahoma Medical Research Foundation and being developed by Oblato, Inc.
AARP CEO A. Barry Rand sent a letter to Members of Congress yesterday in advance of a scheduled vote on legislation to repeal the Affordable Care Act. In his letter, Rand said, "While we respect that there are those who do not support the ACA, AARP opposes repeal because the new law includes many vital provisions important to older Americans and their children."
› Verified 8 days ago
| Entity Name | Indiana University Health Care Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902032832 PECOS PAC ID: 5799755864 Enrollment ID: O20040727000955 |
News Archive
Optimer Pharmaceuticals, Inc. has announced that the United States Patent and Trademark Office issued a production patent (U.S. Patent No. 7,507,564) covering steps used in the manufacture of fidaxomicin, which is currently in its second Phase 3 clinical trial for the treatment of Clostridium difficile infection, or CDI.
Joachim Scholz from Massachusetts General Hospital in Boston, USA and his colleagues studied the symptoms and signs of patients with peripheral neuropathic pain (nerve pain such as sciatica) and non-neuropathic (non-nerve) low back pain to identify the best clinical questions and physical tests for diagnosing pain types.
ValGenesis, Inc., a world-class provider of Validation Lifecycle Management Systems (VLMS), announced today that its innovative ValGenesis Suite 2.5 has achieved SAP certification as powered by the SAP NetWeaver technology platform. Attaining this certified integration status deepens ValGenesis' active and on-going commitment to SAP® solutions.
The U.S. Food and Drug Administration has awarded Rare Pediatric Disease Designation (RPDD) for diffuse intrinsic pontine glioma (DIPG) and Orphan Drug Designation for treatment of malignant glioma to OKN-007, an investigational drug discovered at the Oklahoma Medical Research Foundation and being developed by Oblato, Inc.
AARP CEO A. Barry Rand sent a letter to Members of Congress yesterday in advance of a scheduled vote on legislation to repeal the Affordable Care Act. In his letter, Rand said, "While we respect that there are those who do not support the ACA, AARP opposes repeal because the new law includes many vital provisions important to older Americans and their children."
› Verified 8 days ago
| Entity Name | Indiana Clinic Critical Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417285230 PECOS PAC ID: 3678600988 Enrollment ID: O20100419000408 |
News Archive
Optimer Pharmaceuticals, Inc. has announced that the United States Patent and Trademark Office issued a production patent (U.S. Patent No. 7,507,564) covering steps used in the manufacture of fidaxomicin, which is currently in its second Phase 3 clinical trial for the treatment of Clostridium difficile infection, or CDI.
Joachim Scholz from Massachusetts General Hospital in Boston, USA and his colleagues studied the symptoms and signs of patients with peripheral neuropathic pain (nerve pain such as sciatica) and non-neuropathic (non-nerve) low back pain to identify the best clinical questions and physical tests for diagnosing pain types.
ValGenesis, Inc., a world-class provider of Validation Lifecycle Management Systems (VLMS), announced today that its innovative ValGenesis Suite 2.5 has achieved SAP certification as powered by the SAP NetWeaver technology platform. Attaining this certified integration status deepens ValGenesis' active and on-going commitment to SAP® solutions.
The U.S. Food and Drug Administration has awarded Rare Pediatric Disease Designation (RPDD) for diffuse intrinsic pontine glioma (DIPG) and Orphan Drug Designation for treatment of malignant glioma to OKN-007, an investigational drug discovered at the Oklahoma Medical Research Foundation and being developed by Oblato, Inc.
AARP CEO A. Barry Rand sent a letter to Members of Congress yesterday in advance of a scheduled vote on legislation to repeal the Affordable Care Act. In his letter, Rand said, "While we respect that there are those who do not support the ACA, AARP opposes repeal because the new law includes many vital provisions important to older Americans and their children."
› Verified 8 days ago
| Entity Name | Icem-wishard Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629304134 PECOS PAC ID: 8224162441 Enrollment ID: O20100810000590 |
News Archive
Optimer Pharmaceuticals, Inc. has announced that the United States Patent and Trademark Office issued a production patent (U.S. Patent No. 7,507,564) covering steps used in the manufacture of fidaxomicin, which is currently in its second Phase 3 clinical trial for the treatment of Clostridium difficile infection, or CDI.
Joachim Scholz from Massachusetts General Hospital in Boston, USA and his colleagues studied the symptoms and signs of patients with peripheral neuropathic pain (nerve pain such as sciatica) and non-neuropathic (non-nerve) low back pain to identify the best clinical questions and physical tests for diagnosing pain types.
ValGenesis, Inc., a world-class provider of Validation Lifecycle Management Systems (VLMS), announced today that its innovative ValGenesis Suite 2.5 has achieved SAP certification as powered by the SAP NetWeaver technology platform. Attaining this certified integration status deepens ValGenesis' active and on-going commitment to SAP® solutions.
The U.S. Food and Drug Administration has awarded Rare Pediatric Disease Designation (RPDD) for diffuse intrinsic pontine glioma (DIPG) and Orphan Drug Designation for treatment of malignant glioma to OKN-007, an investigational drug discovered at the Oklahoma Medical Research Foundation and being developed by Oblato, Inc.
AARP CEO A. Barry Rand sent a letter to Members of Congress yesterday in advance of a scheduled vote on legislation to repeal the Affordable Care Act. In his letter, Rand said, "While we respect that there are those who do not support the ACA, AARP opposes repeal because the new law includes many vital provisions important to older Americans and their children."
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Katherine A Pollard, MD 250 N Shadeland Ave, Indianapolis, IN 46219-4959 Ph: () - | Dr Katherine A Pollard, MD 1701 N Senate Blvd, Indianapolis, IN 46202 Ph: (317) 880-3881 |
News Archive
Optimer Pharmaceuticals, Inc. has announced that the United States Patent and Trademark Office issued a production patent (U.S. Patent No. 7,507,564) covering steps used in the manufacture of fidaxomicin, which is currently in its second Phase 3 clinical trial for the treatment of Clostridium difficile infection, or CDI.
Joachim Scholz from Massachusetts General Hospital in Boston, USA and his colleagues studied the symptoms and signs of patients with peripheral neuropathic pain (nerve pain such as sciatica) and non-neuropathic (non-nerve) low back pain to identify the best clinical questions and physical tests for diagnosing pain types.
ValGenesis, Inc., a world-class provider of Validation Lifecycle Management Systems (VLMS), announced today that its innovative ValGenesis Suite 2.5 has achieved SAP certification as powered by the SAP NetWeaver technology platform. Attaining this certified integration status deepens ValGenesis' active and on-going commitment to SAP® solutions.
The U.S. Food and Drug Administration has awarded Rare Pediatric Disease Designation (RPDD) for diffuse intrinsic pontine glioma (DIPG) and Orphan Drug Designation for treatment of malignant glioma to OKN-007, an investigational drug discovered at the Oklahoma Medical Research Foundation and being developed by Oblato, Inc.
AARP CEO A. Barry Rand sent a letter to Members of Congress yesterday in advance of a scheduled vote on legislation to repeal the Affordable Care Act. In his letter, Rand said, "While we respect that there are those who do not support the ACA, AARP opposes repeal because the new law includes many vital provisions important to older Americans and their children."
› Verified 8 days ago
Dr. Gina Marie Diantonio Swartzel, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1701 N Senate Blvd, B401, Indianapolis, IN 46202 Phone: 317-962-5975 | |
Randall M. Todd, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 8111 S Emerson Ave, Indianapolis, IN 46237 Phone: 317-528-5261 Fax: 317-528-5026 | |
Lee G. Wilbur, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1701 N Senate Blvd, Rm Ag001, Indianapolis, IN 46202 Phone: 317-962-3886 Fax: 317-962-8652 | |
Gregory Bauwens, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2001 W 86th St, Indianapolis, IN 46260 Phone: 317-802-3140 | |
Dr. Jennifer Rae Barker, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 702 Barnhill Dr, Riley Hospital, Indianapolis, IN 46202 Phone: 317-274-4034 | |
Gerald William Godfrey, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 8111 S Emerson Ave, Indianapolis, IN 46237 Phone: 131-752-8814 | |
Chris J Hartman, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 720 Eskenazi Ave, Indianapolis, IN 46202 Phone: 317-639-6671 Fax: 317-963-5492 |